Last reviewed · How we verify

Escitalopram + Celecoxib

University of Pennsylvania · FDA-approved active Small molecule

This combination pairs a selective serotonin reuptake inhibitor with a selective cyclooxygenase-2 inhibitor to address both mood and inflammatory symptoms.

This combination pairs a selective serotonin reuptake inhibitor with a selective cyclooxygenase-2 inhibitor to address both mood and inflammatory symptoms. Used for Depression with concurrent pain or inflammatory conditions.

At a glance

Generic nameEscitalopram + Celecoxib
SponsorUniversity of Pennsylvania
Drug classSSRI + selective COX-2 inhibitor combination
TargetSerotonin transporter (SERT) and cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPsychiatry / Pain Management
PhaseFDA-approved

Mechanism of action

Escitalopram increases serotonin availability in the central nervous system by blocking its reuptake, treating depression and anxiety. Celecoxib selectively inhibits COX-2, reducing prostaglandin production and inflammation while sparing COX-1, thereby reducing pain and inflammation with potentially lower gastrointestinal toxicity than non-selective NSAIDs.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: